

# Potential Roles for Rural Ambulance Services in Vaccines and Monoclonal Antibody Infusions



# Logical Partner





Illustration: Aida Amer/Axios









# Scope of Practice

- Before an EMS agency can administer the COVID-19 vaccine, must be authorized under applicable EMS scope of practice

## NOTICES

### DEPARTMENT OF HEALTH

#### Scope of Practice for Emergency Medical Service Providers

[50 Pa.B. 415]

[Saturday, January 18, 2020]

Under 35 Pa.C.S. §§ 8101—8157 (relating to the Emergency Medical Services System Act) and the Department of Health's (Department) regulations in 28 Pa. Code §§ 1023.24(d)(1), 1023.25(d)(1), 1023.26(d)(1), 1023.27(d)(1), 1023.28(d), 1023.29(d) and 1023.30(e), the Department is publishing the scope of practice for emergency medical responders (EMR), emergency medical technicians (EMT), advanced emergency medical technicians (AEMT), paramedics (P), prehospital registered nurses (PHRN), prehospital physician extenders (PHPE) and prehospital physicians (PHP).

# This is a State-by-State Issue

## 2 Examples...



# Pennsylvania

- Current EMS scope of practice, published allows **paramedics** to administer approved immunization
- Many states approving **EMTs**
- Approved Medications Lists allows vaccines for:
  - Advanced Life Support
  - Critical care transport
  - Air ambulance

103 Medications	Immunizations as published in the <i>Pennsylvania Bulletin</i> by the Department	No	No	No	Yes			
		Immunizations	NO	NO	NO	YES <sup>9</sup>	YES <sup>9</sup>	YES <sup>9</sup>



# Texas

- Delegated EMS practice state
- Scope of practice and protocols are determined by agency's **medical director**




Illustration: Sarah Grillo/Axios

Medical Directive # 2012002  
FOR IMMEDIATE DISTRIBUTION  
Date 12/21/2020



Medical Oversight for the MedStar

Effective: 12/21/2020  
Replaces Medical Directive #: N/A  
Subject: COVID-19 Pandemic – Vaccination Procedure

Expiration:

**Purpose:** To outline the procedure for the administration of the Pfizer and Moderna COVID-19 vaccine. These medicinal products have been given Emergency Use Authorization by the FDA for active immunization in individuals to prevent COVID-19 caused by the SARS-CoV-2 virus. This directive may be used by System providers who have completed an OMD-approved training program for COVID vaccine administration.


When functioning as part of a Vaccination Team, parts of this protocol and procedure may be assigned across various team members. Each credentialed provider should ensure that they understand which aspects of this protocol that they and others will be responsible for performing.

**Purpose:** To outline the procedure for the administration of the Pfizer and Moderna COVID-19 vaccine. These medicinal products have been given Emergency Use Authorization by the FDA for active immunization in individuals to prevent COVID-19 caused by the SARS-CoV-2 virus. This directive may be used by System providers who have completed an OMD-approved training program for COVID vaccine administration.


- Monitor patient for 15-minutes for signs and symptoms of adverse reaction
  - If signs and symptoms of adverse reaction, follow Allergic Reaction / Anaphylaxis protocol
- Ensure patients understand importance and time-frame for subsequent dose, if necessary

**Cautions:**

- History of severe allergies or reactions to any medications, foods, vaccines, or latex
- Immunocompromised or on a medication that affects the immune system
- Bleeding disorder or taking blood thinners
- Pregnancy or breastfeeding
- Has received a first dose of another COVID-19 Vaccine
  - Ensure same manufacturer as previous dose



# COVID-19 VACCINATION PROGRAM INTERIM PLAYBOOK FOR JURISDICTION OPERATIONS – October 29, 2020



[https://www.cdc.gov/vaccines/imz-managers/downloads/COVID-19-Vaccination-Program-Interim\\_Playbook.pdf](https://www.cdc.gov/vaccines/imz-managers/downloads/COVID-19-Vaccination-Program-Interim_Playbook.pdf)

PRODUCT	NEW/UPDATE	ADDITIONAL INFORMATION
<i>Vaccine Storage and Handling Toolkit</i>	Update	An addendum with general COVID-19 vaccine storage, handling and transport information will be added, and the addendum will be updated as COVID-19 vaccine products are approved. A fully updated toolkit, incorporating COVID-19 information into the actual toolkit will not be issued until 2022.
COVID-19 training module	New	Under development is a web-based module. Topics will include storage/handling, vaccine indications, contraindications/precautions, administration, and documentation. It will not have CE and will be amended as new COVID-19 vaccine products are introduced.
Vaccine product summary sheets	New	Fact sheets with storage, handling, preparation, indications, contraindications/precautions, and administration will be developed for each vaccine
Additional immunization guidance materials	New	More extensive information related to storage, handling, preparation, administration, shipping, packaging, and transport will be provided as necessary (not all vaccines will need additional guidance)
Comprehensive table of vaccine products	New	A table of COVID-19 vaccine products with key information will be updated as vaccines are approved.
Beyond use dates and expiration date tracking tools	New	A resource will be provided to track BUD and expiration dates, for use early in vaccine distribution process.




Illustration: Eniola Odetunde/Axios

# Example: Texas Immunization Program Portal

## Welcome to the Texas DSHS Immunization Program Portal

Here health care providers and pharmacies may register to be considered to receive COVID-19 vaccine.



 [Learn more about becoming a COVID-19 vaccine provider](#)

**Browser Compatibility Notice:** For the best results using this application use the latest versions of Google Chrome or Microsoft Edge.

Please allow up to 14 days for processing of enrollment during this busy time.

# Information to be Provided:

- Vaccine coordinator contact information
- Vaccine delivery times
- Vaccine storage capacity
- The patient profile of the population served





# Other Requirements in Texas




- Administering and reporting information (ImmTrac2)
- List of responsible personnel such as the Chief Medical Officer or Medical Director
- Sign and agree to the conditions in the **CDC COVID-19 Vaccination Program Provider Agreement**

A screenshot of the ImmTrac2 Texas Immunization Registry website. The page has a blue header with the Texas Department of State Health Services logo on the left and the 'ImmTrac2 Texas Immunization Registry' title in the center. Below the header is a navigation bar with links for HOME, FORMS, REGISTRATION, and RELATED LINKS. On the left side, there is a login section with fields for Org Code (TRA1000), Username (AB1234CD), and Password, followed by a Login button. Below the login section is a warning: 'DO NOT ATTEMPT TO LOG ON UNLESS YOU ARE AN AUTHORIZED USER.' At the bottom left is a 'Forgot Password?' link. The main content area features a 'Hot Topics' section with a 'Last Topic' box containing the text 'This is our last topic www.google.com www.google.com' and a date 'Posted on 12/08/2016'. To the right of the 'Last Topic' box are links for 'HT-1' and 'HT-2'. Below the 'Hot Topics' section are several blue links: 'About ImmTrac', 'ImmTrac is a Lifetime Registry', 'About the Texas Vaccines for Children Program', 'Meaningful Use Information', and 'Vaccine Education Online'. At the bottom center, there is a copyright notice: 'Copyright © 1999 - 2017 State of Wisconsin. All rights reserved.'

## Vaccines & Immunizations

[CDC](#) > [Vaccines and Immunizations Home](#) > [COVID-19 Vaccination](#) > [COVID-19 Vaccination Planning](#)



 [Vaccines and Immunizations Home](#)

[For Parents](#)

[For Adults](#)

[For Pregnant Women](#)

[For Healthcare Professionals](#)

[COVID-19 Vaccination](#) —

[For Healthcare Professionals](#) +

[COVID-19 Vaccination Planning](#) —

[COVID-19 Vaccination Program Operational Guidance](#)

[COVID-19 Vaccination Provider Support](#)

[Long-term Care Pharmacy Partnerships](#)

# COVID-19 Vaccination Provider Support

## Data and Reporting

All COVID-19 vaccination providers must report COVID-19 vaccine inventory daily into VaccineFinder. In some jurisdictions, providers may report vaccine inventory to the jurisdiction's IIS for the jurisdiction to upload into VaccineFinder. If you have questions about the process for your jurisdiction, please contact your jurisdiction's immunization program.

[VaccineFinder Info](#)

COVID-19 vaccination providers must document vaccine administration in their medical record systems within 24 hours of administration, and use their best efforts to report administration data to the relevant system for the jurisdiction (i.e., IIS) as soon as practicable and no later than 72 hours after administration.

[Enrolling in your jurisdiction/state-based IIS system](#)

[Add the COVID-19 vaccine label to your VTrckS profile](#)

[Get CDC's Comprehensive Vaccine Data Requirements !\[\]\(26cddea01ddf7f002af4ba779c4999ee\_img.jpg\)](#)

[Get COVID-19 Vaccination reporting specifications !\[\]\(b78e2d0769ad682766c36e077fde3d60\_img.jpg\)](#)

## CDC COVID-19 Vaccination Program Provider Agreement



Please complete Sections A and B of this form as follows:

The Centers for Disease Control and Prevention (CDC) greatly appreciates your organization's (Organization) participation in the CDC COVID-19 Vaccination Program. Your Organization's chief medical officer (or equivalent) and chief executive officer (or chief fiduciary)—collectively, Responsible Officers—must complete and sign the *CDC COVID-19 Vaccination Program Provider Requirements and Legal Agreement* (Section A). *CDC COVID-19 Vaccination Program Provider Profile Information* (Section B) must be completed for each vaccination Location covered under the Organization listed in Section A.

### Section A. COVID-19 Vaccination Program Provider Requirements and Legal Agreement

ORGANIZATION IDENTIFICATION		
Organization's legal name:		
Number of affiliated vaccination locations covered by this agreement: _____		
Organization telephone number:	Email (must be monitored and will serve as dedicated contact method for the COVID-19 Vaccination Program):	
Organization address:		
RESPONSIBLE OFFICERS		
For the purposes of this agreement, in addition to Organization, Responsible Officers named below will also be accountable for compliance with the conditions specified in this agreement. The individuals listed below must provide their signature after reviewing the agreement requirements.		
Chief Medical Officer (or Equivalent) Information		
Last name	First name	Middle initial
Title	Licensure (state and number)	
Telephone number:	Email:	
Address:		
Chief Executive Officer (or Chief Fiduciary) Information		
Last name	First name	Middle initial
Telephone number:	Email:	
Address:		

**May vary by state**

## CDC COVID-19 Vaccination Program Provider Agreement



Please complete Sections A and B of this form as follows:

The Centers for Disease Control and Prevention (CDC) greatly appreciates your organization's (Organization) participation in the CDC COVID-19 Vaccination Program. Your Organization's chief medical officer (or equivalent) and chief executive officer (or chief fiduciary)—collectively, Responsible Officers—must complete and sign the *CDC COVID-19 Vaccination Program Provider Requirements and Legal Agreement* (Section A). *CDC COVID-19 Vaccination Program Provider Profile Information* (Section B) must be completed for each vaccination Location covered under the Organization listed in Section A.

### Section A. COVID-19 Vaccination Program Provider Requirements and Legal Agreement

ORGANIZATION IDENTIFICATION	
Organization's legal name:	
Number of affiliated vaccination locations covered by this agreement: _____	
Organization telephone number:	Email (must be monitored and will serve as dedicated contact method for the COVID-19 Vaccination Program):
Organization address:	

## CDC COVID-19 Vaccination Program Provider Agreement

AGREEMENT REQUIREMENTS	
I understand this is an agreement between Organization and CDC. This program is a part of collaboration under the relevant state, local, or territorial immunization's cooperative agreement with CDC. To receive one or more of the publicly funded COVID-19 vaccines (COVID-19 Vaccine), constituent products, and ancillary supplies at no cost, Organization agrees that it will adhere to the following requirements:	
1.	Organization must administer COVID-19 Vaccine in accordance with all requirements and recommendations of CDC and CDC's Advisory Committee on Immunization Practices (ACIP). <sup>1</sup>
2.	<p>Within 24 hours of administering a dose of COVID-19 Vaccine and adjuvant (if applicable), Organization must record in the vaccine recipient's record and report required information to the relevant state, local, or territorial public health authority. Details of required information (collectively, Vaccine-Administration Data) for reporting can be found on CDC's website.<sup>2</sup></p> <p>Organization must submit Vaccine-Administration Data through either (1) the immunization information system (IIS) of the state and local or territorial jurisdiction or (2) another system designated by CDC according to CDC documentation and data requirements.<sup>2</sup></p> <p>Organization must preserve the record for at least 3 years following vaccination, or longer if required by state, local, or territorial law. Such records must be made available to any federal, state, local, or territorial public health department to the extent authorized by law.</p>
3.	Organization must not sell or seek reimbursement for COVID-19 Vaccine and any adjuvant, syringes, needles, or other constituent products and ancillary supplies that the federal government provides without cost to Organization.
4.	Organization must administer COVID-19 Vaccine regardless of the vaccine recipient's ability to pay COVID-19 Vaccine administration fees.

5.	Before administering COVID-19 Vaccine, Organization must provide an approved Emergency Use Authorization (EUA) fact sheet or vaccine information statement (VIS), as required, to each vaccine recipient, the adult caregiver accompanying the recipient, or other legal representative.
6.	Organization's COVID-19 vaccination services must be conducted in compliance with CDC's Guidance for Immunization Services During the COVID-19 Pandemic for safe delivery of vaccines. <sup>3</sup>
7.	<p>Organization must comply with CDC requirements for COVID-19 Vaccine management. Those requirements include the following:</p> <ul style="list-style-type: none"> <li>a) Organization must store and handle COVID-19 Vaccine under proper conditions, including maintaining cold chain conditions and chain of custody at all times in accordance with the manufacturer's package insert and CDC guidance in CDC's Vaccine Storage and Handling Toolkit<sup>4</sup>, which will be updated to include specific information related to COVID-19 Vaccine;</li> <li>b) Organization must monitor vaccine-storage-unit temperatures at all times using equipment and practices that comply with guidance located in CDC's Vaccine Storage and Handling Toolkit<sup>4</sup>;</li> <li>c) Organization must comply with each relevant jurisdiction's immunization program guidance for dealing with temperature excursions;</li> </ul>

This agreement expressly incorporates all recommendations, requirements, and other guidance that this agreement specifically identifies through footnoted weblinks. Organization must monitor such identified guidance for updates. Organization must comply with such updates.


<sup>1</sup> <https://www.cdc.gov/vaccines/hcp/acip-recs/index.html>

<sup>2</sup> <https://www.cdc.gov/vaccines/programs/iis/index.html>

<sup>3</sup> <https://www.cdc.gov/vaccines/pandemic-guidance/index.html>

<sup>4</sup> <https://www.cdc.gov/vaccines/hcp/admin/storage-handling.html>

## Enroll in Medicare as Mass Immunizer to Roster Bill





Institutional	Non-Institutional	Durable Medical Equipment (DME)
<ul style="list-style-type: none"> <li>• Outpatient Physical Therapy</li> <li>• Occupational Therapy</li> <li>• Speech Pathology Services</li> <li>• Histocompatibility Laboratory</li> <li>• Religious Non-Medical Health Care Institution</li> </ul>	<ul style="list-style-type: none"> <li>• Independent Clinical Laboratory</li> <li>• Ambulance Service Supplier</li> <li>• Independent Diagnostic Testing Facility</li> <li>• Intensive Cardiac Rehabilitation Supplier</li> <li>• Mammography Center</li> <li>• Medicare Diabetes Prevention Program Suppliers</li> <li>• Portable X-ray Supplier</li> <li>• Radiation Therapy Center</li> <li>• Opioid Treatment Program</li> <li>• Organ Procurement Organization</li> <li>• Home Infusion Therapy Supplier</li> </ul>	<ul style="list-style-type: none"> <li>• Durable Medical Equipment Supplier</li> <li>• Pharmacy (enrolled as DME supplier)</li> </ul>

<https://www.cms.gov/covidvax-provider>

# COVID-19 MAC Webpages and Hotlines

Only contact the COVID-19 Hotline for the Medicare Administrative Contractor (MAC) that serves your geographic area.

Medicare Administrative Contractor (links to webpages)	States and Territories per MAC Jurisdiction	Toll-free Hotline Telephone Number	Hotline Hours of Operation, Monday – Friday
<a href="#">CGS Administrators, LLC (CGS)</a>	<b>Part A/B:</b> J15: Kentucky, Ohio  <b>Home Health &amp; Hospice:</b> J15: Colorado, Delaware, District of Columbia, Iowa, Kansas, Maryland, Missouri, Montana, Nebraska, North Dakota, Pennsylvania, South Dakota, Utah, Virginia, West Virginia, Wyoming	1-855-769-9920	7:00 am – 4:00 pm CT
<a href="#">First Coast Service Options Inc. (FCSO)</a>	JN: Florida, Puerto Rico, U.S. Virgin Islands	1-855-247-8428	8:30 am – 4:00 pm ET

<https://www.cms.gov/files/document/covid-19-mac-webpages-and-hotlines.pdf>

**Payment Allowances and Effective Dates for COVID-19 Vaccines and their Administration during the Public Health Emergency:**

Code	CPT Short Descriptor	Labeler Name	Vaccine/Procedure Name	Payment Allowance	Effective Dates
91300	SARSCOV2 VAC 30MCG/0.3ML IM	Pfizer	Pfizer-Biontech Covid-19 Vaccine	\$0.010*	xx/xx/xxxx – TBD
0001A	ADM SARSCOV2 30MCG/0.3ML 1ST	Pfizer	Pfizer-Biontech Covid-19 Vaccine Administration – First Dose	\$16.940**	xx/xx/xxxx – TBD
0002A	ADM SARSCOV2 30MCG/0.3ML 2ND	Pfizer	Pfizer-Biontech Covid-19 Vaccine Administration – Second Dose	\$28.390**	xx/xx/xxxx – TBD
91301	SARSCOV2 VAC 100MCG/0.5ML IM	Moderna	Moderna Covid-19 Vaccine	\$0.010*	xx/xx/xxxx – TBD
0011A	ADM SARSCOV2 100MCG/0.5ML1ST	Moderna	Moderna Covid-19 Vaccine Administration – First Dose	\$16.940**	xx/xx/xxxx – TBD
0012A	ADM SARSCOV2 100MCG/0.5ML2ND	Moderna	Moderna Covid-19 Vaccine Administration – Second Dose	\$28.390**	xx/xx/xxxx – TBD

\* Since we anticipate that providers, initially, will not incur a cost for the product, CMS will update the payment allowance at a later date. Providers should not bill for the product if they received it for free.

\*\* These rates will also be geographically adjusted for many providers. Certain settings utilize other payment methodologies, such as payment based on reasonable costs.



MEDICARE

---

12/7/2020

METROPOLITAN AREA EMS AUTHORITY  
2900 ALTA MERE DR  
FT WORTH, TX 76116

Attention: MATT ZAVADSKY

Reference: National Provider Identifier (NPI): [REDACTED]  
Provider Transaction Access Number (PTAN) [REDACTED]

Dear METROPOLITAN AREA EMS AUTHORITY:

This letter is written confirmation that you have been granted temporary Medicare billing privileges pursuant to the CMS waiver of certain enrollment and screening requirements during the national emergencies associated with COVID-19. These temporary billing privileges are being established per a phone call on DECEMBER 7, 2020. Temporary billing privileges are being established to provide mass immunization services. Listed above are your National Provider Identifier (NPI) and Provider Transaction Access Number (PTAN).

## Eli Lilly says monoclonal antibody cocktail cuts hospitalizations by 70% for high-risk COVID-19 patients

Karen Weintraub, Jan. 26, 2021

While vaccines may help slow the COVID-19 pandemic over the next months, drug company Eli Lilly announced Tuesday that its treatments can help save lives in the meantime.

The company's drug bamlanivimab was authorized by the U.S. Food and Drug Administration late last year and has been used by 125,000 high-risk patients nationwide based on early-stage data suggesting it could be effective.

The drug is a monoclonal antibody, meaning it mimics one of the natural antibodies the immune system uses to fight off the virus.

Former President Donald Trump as well as former New Jersey Gov. Chris Christie and former New York City Mayor Rudy Giuliani [all received monoclonal antibodies](#) shortly after they were diagnosed with COVID-19.

[In a large, late-stage study the company unveiled Tuesday](#), bamlanivimab combined with another monoclonal antibody, etesevimab, was found to be extremely effective in high-risk patients diagnosed with COVID-19.



<https://www.usatoday.com/story/news/health/2021/01/26/eli-lilly-monoclonal-antibodies-high-risk-covid-19-patients-coronavirus/4263087001/>



**FACT SHEET FOR HEALTH CARE PROVIDERS  
EMERGENCY USE AUTHORIZATION (EUA) OF BAMLANIVIMAB**

**AUTHORIZED USE**

The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product bamlanivimab for the treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients with positive results of direct SARS-CoV-2 viral testing who are 12 years of age and older weighing at least 40 kg, and who are at high risk for progressing to severe COVID-19 and/or hospitalization.

**LIMITATIONS OF AUTHORIZED USE**

- Bamlanivimab is not authorized for use in patients:
  - who are hospitalized due to COVID-19, OR
  - who require oxygen therapy due to COVID-19, OR
  - who require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity.
- Benefit of treatment with bamlanivimab has not been observed in patients hospitalized due to COVID-19. Monoclonal antibodies, such as bamlanivimab, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation.




**Payment Allowances and Effective Dates for COVID-19 Monoclonal Antibodies and their Administration during the Public Health Emergency:**

Code	CPT Short Descriptor	Labeler Name	Vaccine/Procedure Name	Payment Allowance	Effective Dates
Q0239	bamlanivimab-xxxx	Eli Lilly	Injection, bamlanivimab, 700 mg	\$0.010*	11/10/2020 – TBD
M0239	bamlanivimab-xxxx infusion	Eli Lilly	Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring	\$309.600***	11/10/2020 – TBD
Q0243	casirivimab and imdevimab	Regeneron	Injection, casirivimab and imdevimab, 2400 mg	\$0.010*	11/21/2020 – TBD
M0243	casirivi and imdevi infusion	Regeneron	intravenous infusion, casirivimab and imdevimab includes infusion and post administration monitoring	\$309.600***	11/21/2020 – TBD


\* Since we anticipate that providers, initially, will not incur a cost for the product, CMS will update the payment allowance at a later date. Providers should not bill for the product if they received it for free.

\*\*\* Medicare will pay a rate of \$309.60 for many providers. These rates will also be geographically adjusted for many providers. Certain settings utilize other payment methodologies, such as payment based on reasonable costs.

**Is your agency participating in administering  
COVID vaccines to the public?**



**If Yes, are you staffing other clinics,  
or doing your own?**




## **What has been your #1 "Ah Ha" moment regarding participating in COVID vaccine administration?**

### **What advice would you give to other EMS agencies considering getting involved in vaccine administration?**

- Registration and scheduling have to be very organized and clearly communicated to the public
- Bureaucratic road blocks
- Prove our value, get involved
- It is imperative to have an understanding of how much vaccine is available, in order to accurately and adequately staff the clinic. It is also important to ensure that minimum staffing is achieved to reduce back-ups and increased wait times
- lack of prehospital involvement in the planning of vaccine administration, overlooking a huge resource but training pharmacy techs instead
- Train with DPH or hospital systems to learn how to effectively manage large crowds with minimal staffing, immunization documentation, CMS roster billing
- Being prepared for the data entry and logistics of hosting the clinics ahead of time. The more work is done prior to hosting a clinic, the better and smoother the clinic runs.
- Work closely with your Local Public Health officials to work and plan for EMS involvement in vaccine administration
- Stay focused on making a positive and compassionate impression with the public
- It is positive interaction that can lead to increased public confidence in future areas


**CMS allows ambulance agencies to be reimbursed for vaccine administration.**

**If you are doing your own clinics, are you planning to bill,  
or already billing for the vaccine administration?**






Is your agency participating in *monoclonal antibody* (mAb) infusions for the public?



If Yes, are you staffing other infusion centers, or doing your own?




**What has been your #1 "Ah Ha" moment regarding participating in mAb infusions?**

**What advice would you give to other EMS agencies considering getting involved in mAb infusions?**

- Be aware of the State's ordering process
- It is an issue of resource management and patient flow
- We do the mAb infusion in place at LTC and LTAC so we don't use resources to move them for the infusion
- We are trying to assist filling gaps within the local health care systems because of lack of capacity to meet the growing demand during this pandemic. There were challenges with scope of practice when working in non-urgent areas.

## Service area type



## Rural and Frontier Breakdown

### Is your agency participating in administering COVID vaccines to the public?

Yes	62%
No	38%

### Are you staffing other clinics, or doing your own??


Doing our Own	44%
Staffing Others	22%
Both	11%
Other	22%

### Tips:

- Know who your Community partners are in assisting with the vaccination program. Your partners vary from one county to another.
- Close collaboration with Public Health has been instrumental
- Planning for employee sick time due to side effects
- Vaccine is coming in very slow to our community.









# Other Roles Discussed w/Flex Participants

- **COVID Testing**
  - On-site and in-home
- **Alternate dispositions for potential COVID+ patients**
  - Treatment in Place
  - Alternate Destinations
- **Telemedicine facilitation**
  - On 9-1-1 calls or pre-scheduled
  - Station-Based clinics
- **Follow-up care after discharge**
  - Reduce Length of Stay/Observation Admissions
- **Subscription service**
  - Basic + enhanced services on demand





thank you!